A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Clinical trial NCT04720716 · COMPLETED
Trial details
- NCT number
- NCT04720716
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-07
- Primary completion
- 2025-12-31
- Enrollment
- 344
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.